Sun Pharma gets FDA approval for diabetes generic drug

Fri Jul 12, 2013 8:40am IST

Related Topics

Stocks

   

REUTERS - Sun Pharmaceutical Industries(SUN.NS) said on Friday it has received final approval from the United States Food and Drug Administration (FDA) to launch the generic version of Novo Nordisk's (NOVOb.CO) Prandin diabetes drug.

Prandin, known chemically as repaglinide, and its combination with the commonly prescribed type 2 diabetes drug metformin, sold as PrandiMet, had sales of about $200 million in 2012 for Novo.

Sun Pharma said it would be eligible for a 180-day marketing exclusivity in the United States for the drug.

A U.S. appeals court last month found the patent on Novo's Prandin diabetes drug in combination with metformin to be invalid, paving the way for the introduction of a generic version of the drug.

(Reporting by Sumeet Chatterjee in MUMBAI; Editing by Supriya Kurane)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Kerry in India

REUTERS SHOWCASE

Deadly Landslide

Deadly Landslide

Landslide near Pune kills 10, scores feared trapped.  Full Article 

Fed Policy

Fed Policy

Fed presses forward with bond buying, cites uptick in inflation.  Full Article 

Big Infra Deal

Big Infra Deal

Piramal, Dutch APG tie up for $1 bln infra investment  Full Article 

E-Commerce

E-Commerce

Amazon says to invest $2 billion more in India   Full Article 

Lupin Results

Lupin Results

Q1 net profit up 56 percent on higher U.S. drug sales   Full Article 

Smuggling Gold

Smuggling Gold

Air India staff found smuggling gold  Full Article 

Economy Reboots

Economy Reboots

U.S. economy back on track with strong second-quarter rebound .  Full Article 

Auto Sector

Auto Sector

VW closes in on Toyota as global auto leader  Full Article 

Expanding Reach

Expanding Reach

Tata to invest $35 bln over 3 years, focus on new businesses   Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage